Agenus Inc. (NASDAQ:AGEN) Receives Average Recommendation of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned a consensus recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $10.00.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Thursday, December 5th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Barclays PLC increased its position in Agenus by 295.3% during the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 20,777 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Agenus by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after buying an additional 32,016 shares during the period. EP Wealth Advisors LLC acquired a new stake in shares of Agenus during the 3rd quarter worth $55,000. State Street Corp increased its holdings in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after buying an additional 9,731 shares during the last quarter. Finally, Point72 DIFC Ltd raised its position in shares of Agenus by 380.0% in the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after buying an additional 11,542 shares during the period. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Price Performance

Shares of NASDAQ AGEN opened at $2.83 on Monday. The company has a 50-day simple moving average of $3.67 and a 200-day simple moving average of $7.16. The company has a market cap of $66.39 million, a PE ratio of -0.25 and a beta of 1.24. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.